A proof-of-concept clinical example is the identification of a drug with the intestinal organoids derived from a cystic fibrosis patient carrying a rare CFTR mutation, and the drug named Kalydeco was shown to be effective (Saini, 2016). This evidence concerns the gene CFTR and cystic fibrosis.